Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)

November 16, 2026 updated by: Istituto Ortopedico Rizzoli

Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)

The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:

  • How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
  • Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.

During a single clinic visit, participants will:

  • Have standard x-rays of their hands and wrists
  • Have a routine ultrasound of their hands and wrists
  • Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.

High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.

To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.

At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Bologna
      • Bologna, Bologna, Italy, 40136
        • IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
    • Verona
      • Verona, Verona, Italy, 37134
        • Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Rheumatoid Arthritis (RA) Cohort:

  • Age ≥ 60 years
  • Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
  • Clinical diagnosis confirmed by an expert rheumatologist
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Calcium Pyrophosphate Deposition (CPPD) Cohort:

  • Age ≥ 60 years
  • Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Control Cohort (Non-inflammatory Controls):

  • Age ≥ 60 years
  • Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
  • Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
  • Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
  • Written informed consent obtained

Exclusion Criteria:

All Cohorts:

  • Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
  • Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
  • Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
  • Inability to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Rheumatoid Arthritis (RA) Cohort

Patients with RA and current or prior hand/wrist involvement (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Other Names:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Active Comparator: Healthy / Non-inflammatory Controls

Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Other Names:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Active Comparator: CPPD Positive Control Cohort

Patients with proven CPPD disease (n = 20).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Other Names:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Time Frame: Baseline (single imaging visit)

Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.

Baseline (single imaging visit)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of HR-pQCT-positive cases missed by conventional imaging
Time Frame: Baseline (single imaging visit)

Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.

Baseline (single imaging visit)
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.

Baseline (single imaging visit)
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)

Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.

Baseline (single imaging visit)
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)

Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.

Baseline (single imaging visit)
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)

Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.

Baseline (single imaging visit)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Time Frame: Baseline (single imaging visit)

Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.

Baseline (single imaging visit)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

April 30, 2029

Study Completion (Estimated)

October 31, 2029

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HAND-QCT-RA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.